Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol

Journal of Research in Medical Sciences

Volumn 17, Issue 11, 2012, Pages 1063-1066

  Rabati, Behnaz Khani ^a   Zeidi, Setare Nasiri ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Assisted reproductive techniques; Gonadotropin releasing hormone agonist; Gonadotropin releasing hormone antagonist; Ovarian hyper stimulation syndrome; Ovarian stimulation; Pregnancy rate

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; DRUG DOSE REDUCTION; ECHOGRAPHY; ENDOMETRIAL THICKNESS; ESTRADIOL BLOOD LEVEL; ETHICS; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTERVENTION STUDY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY OUTCOME; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; STIMULATION; TRANSVAGINAL ECHOGRAPHY;

EID: 84875068775     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170-207.
2. Santos MA, Kuijk EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction 2010;139:23-34.
3. Al-Inany H, Wahba A, Peitsidis P. Changing attitudes in ovarian stimulation. Womens Health (Lond Engl) 2011;7:505-7.
4. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-51.
5. Felberbaum RE, Reissmann T, Küpker W, Bauer O, al Hasani S, Diedrich C, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 1995;61:151-5.
6. Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: Results of a prospective, randomized study. Hum Reprod 2002;17:2842-5.
7. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: ACochrane review. Hum Reprod 2002;17:874-85.
8. Firouzabadi RD, Ahmadi S, Oskouian H, Davar R. Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Arch Gynecol Obstet 2010;281:81-5.
9. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: Aprospective randomized study. Hum Reprod 2004;19:1979-84.
10. Berin I, Stein DE, Keltz MD. Acomparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing invitro fertilization. Fertil Steril 2010;93:360-3.
11. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: Randomized controlled trial. Reprod Biomed Online 2004;8:524-7.
12. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome-views and ideas. Hum Reprod 1997;12:1129-37.
13. Knox CL, Allan JA, Allan JM, Edirisinghe WR, Stenzel D, Lawrence FA, et al. Ureaplasma parvum and Ureaplasma urealyticum are detected in semen after washing before assisted reproductive technology procedures. Fertil Steril 2003;80:921-9.
14. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-96.
15. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45
16. Tarlatzis B. C, Kolibianakis E.M. GnRH agonist vs. antagonist. Clinical obstetrics and Gynecology 2007:21:57-65
17. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333-40.
18. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, et al. Gonadotropin-releasing hormone antagonist protocol: Anovel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001;97:202-7.
19. Varney NR, Syrop C, Kubu CS, Struchen M, Hahn S, Franzen K. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. JAssist Reprod Genet 1993;10:53-7.
20. Tazegül A, Görkemli H, Ozdemir S, Aktan TM. Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing invitro fertilization: Arandomized controlled trial. Arch Gynecol Obstet 2008;278:467-72.
21. Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A, et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: Effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 2005;120:185-9.
22. Sirayapiwat P, Suwajanakorn S, Triratanachat S, Niruthisard S. The effects of GnRH antagonist on the endometrium of normally menstruating women. JAssist Reprod Genet 2007;24:579-86.
23. Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked? Clin Exp Obstet Gynecol 2006;33:197-9.